Lupin receives U.S. approval for another drug
Facebook Twitter google+ RSS Feed

Lupin receives U.S. approval for another drug

Thursday, 31 July 2008, 07:00 Hrs
Printer Print Email Email
New Delhi: Drug major Lupin announced Thursday that its U.S. subsidiary, Lupin Pharmaceuticals (LPI) has received final approval for the company's Abbreviated New Drug Application (ANDA) for divalproex sodium delayed-release tablets from the U.S. Food and Drug Administration (FDA).

The tablets will be available in 125 mg, 250 mg and 500 mg variants. Commercial shipments have commenced, the company said in a regulatory statement Thursday.

With the approval of this tablet the cumulative ANDA approvals of the company stand at 31 with 34 pending approval from the FDA.
Source: IANS
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Sr. Executive
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
Reena Khanna
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset